Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
G Neumayr Medical and Intensive Care Unit,
Department of Internal Medicine, University of Innsbruck, A-6020
Innsbruck, Austria
Correspondence to: Dr Neumayr
For about 30 years electrical cardioversion has been
routine for converting arrhythmias.1 Whether the
application of shocks in the usual dosage is safe is still
controversial as minimal myocardial cell injury cannot be
excluded.2 If simultaneous muscle damage occurs the
measurement of common cardiac markers, especially creatine kinase and
its isoenzyme creatine kinase MB, lacks specificity. We therefore
also measured the concentration of cardiac troponin T as this is
the most sensitive and specific marker to date.
Over the past three years in this unit 69 non-selected
patients with atrial fibrillation (aged 21-87, mean 63.7 years)
underwent elective countershock using a direct current. Serum samples
were taken before and 24 hours after cardioversion. The concentrations of cardiac troponin T, total creatine kinase, and creatine kinase MB were measured by enzyme linked immunosorbent assay (Boehringer, Germany) (reference ranges <0.1 µg/l, 10-80 U/l, and <12 U/l, <6% respectively). A total of 153 shocks was delivered, amounting to
an average cumulative energy of 286 J per patient. Cardioversion was started with 50 J of stored energy, and subsequent shocks comprised 100, 200, 300, and 360 J. The procedure was terminated after restoration of sinus rhythm or after two attempts of 360 J each.
Four patients received the highest amount of cumulative energy (1370 J). Sixty seven patients converted to sinus rhythm, and no major
complications occurred. At follow up 24 hours later 60 patients had
restored sinus rhythm. All measurements of cardiac troponin T activity
before and after cardioversion were below 0.1 µg/l. The baseline
concentrations and peak activities of creatine kinase and creatine
kinase MB were within the normal range except in three cases. In one
patient the peak activity of total creatine kinase increased from 13 to
103 U/l but that of creatine kinase MB was normal. In the other two
patients the peak activity of creatine kinase was increased from 32 to
363 U/l and from 18 to 512 U/l and that of creatine kinase MB by
33 U/l and by 42 U/l respectively.
Experiments in animals have shown that necrosis of myocardial
cells occurs after repeated countershocks using direct currents of high
energy.3 Evidence that electrical cardioversion may result
in myocardial damage in humans is based on the increased concentrations
of various cardiac enzymes measured after cardioversion.4
To overcome the problem of insufficient specifity of cardiac enzymes we
measured the activity of cardiac troponin T. Cardiac troponin T is not
detectable in the serum of healthy people and can be differentiated
from its isoforms in skeletal muscle by immunological techniques; its
cross reactivity to mixed skeletal muscle is 1-2%, and its specificity
is 95% in the presence of skeletal damage.5 Currently,
cardiac troponin T is the best marker for detecting minimal
myocardial damage, especially when skeletal muscles are also injured.
In our non-selected patient population countershock using direct
current was highly effective and without major complications. As we
did not find any increase in plasma activity of cardiac troponin T we
conclude that myocardial cell injury by electrical cardioversion is unlikely when applying cumulative energies of up
to 1370 J. As two patients had raised concentrations of total creatine kinase and creatine kinase MB but not of cardiac troponin T,
we conclude that these enzymes originated from injured skeletal muscle.
We therefore suggest that the increased concentrations of creatine
kinase and creatine kinase MB reported previously in cases of
myocardial damage could also have originated from injured skeletal
muscle.
Contributors: GN is guarantor for the paper. PS, GF, HG, and
CJW contributed to the study design, analysis of the data, and revision
of the paper.
Funding: None.
Conflict of interest: None.
(Accepted 27 November 1997)
![]()
Patients, methods, and results
![]()
Comment
![]()
Acknowledgments
![]()
References
Top
References
© BMJ 1998